Skip to content
StackItSmart
AHuman RCT or meta-analysis

Metformin

Glucophage

Metformin (Glucophage) is an oral biguanide and the first-line drug for type 2 diabetes. In a harm-reduction / physique context it is used off-label as a metabolic-support ("ancillary") agent for its modest weight/appetite reduction and insulin-sensitizing effects, but there is no adequate human data supporting metformin for body-composition, nutrient-partitioning, or performance-enhancement use — those claims are unproven. It is not anabolic, androgenic, or hormonal. The main risks are (1) metformin-associated lactic acidosis (MALA), a rare but potentially fatal emergency that clusters in renal impairment, acute illness (sepsis, dehydration, hypoxia), heavy alcohol use, and overdose; (2) long-term vitamin B12 depletion; and (3) frequent gastrointestinal side effects (diarrhea, nausea, cramping). It is renally cleared and accumulates when kidney function drops, which is the central safety pivot. This monograph is educational, is not medical advice, and does not tell anyone how to dose to maximize any effect — decisions about metformin belong with a physician.

Clinical readoutAncillary · metabolic-support
Hepatic strainLow
CardiovascularNone
HPTA suppressionNone
Half-life
5 h
Route
Oral
Evidence
A
Active
Immediate-release requi…
5 h10 h15 h20 h25 h
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Plasma elimination half-life approximately 5 hours during multiple dosing in people with good renal function; a longer terminal phase reflects erythrocyte partitioning. Half-life is prolonged in renal impairment, which drives accumulation and MALA risk.
Pharmacology

Mechanism of action

Metformin lowers blood glucose primarily by suppressing hepatic gluconeogenesis (hepatic glucose output) rather than by stimulating insulin secretion, so it does not cause hypoglycemia as monotherapy. The dominant proposed mechanism is mild, transient inhibition of mitochondrial respiratory-chain complex I, which lowers hepatic energy charge and, via a rise in AMP:ATP, activates AMP-activated protein kinase (AMPK) and blunts glucagon-stimulated cAMP/PKA signaling; AMPK activation contributes mainly to improved insulin sensitivity and lipid handling and is dispensable for the acute glucose-lowering effect. At clinically achieved concentrations (roughly 50-100 microM, well below the >1 mM used in many cell studies) a redox-dependent, substrate-selective inhibition of gluconeogenesis has been described. Metformin is a hydrophilic cation whose cellular uptake and clearance depend on organic cation transporters (OCT1/OCT3) and MATE transporters. Its mechanism is metabolic, not hormonal — it has no direct action on androgen receptors or the reproductive hormone axis.
Kinetics

Pharmacokinetics

Half-life

Plasma elimination half-life approximately 5 hours during multiple dosing in people with good renal function; a longer terminal phase reflects erythrocyte partitioning. Half-life is prolonged in renal impairment, which drives accumulation and MALA risk.

Active duration

Immediate-release requires 2-3 daily doses; extended-release (XR) formulations allow once-daily dosing with improved gastrointestinal tolerability. Duration is stated for clinical monitoring/washout, not to evade any testing.

Route

Oral. Oral bioavailability ~55% (±16%); absorbed predominantly from the small intestine.

Metabolism & clearance

Not metabolized — excreted unchanged in the urine, largely via active tubular secretion by organic cation transporters (renal clearance ~510 mL/min, far exceeding creatinine clearance). Because clearance falls in proportion to declining renal function, plasma levels rise in renal impairment; maintaining mean plasma concentrations below ~2.5 mg/L is suggested to minimize lactic-acidosis risk.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Lowers fasting plasma glucose and HbA1c in type 2 diabetes without causing hypoglycemia as monotherapy (UKPDS 34)
  • Reduces hepatic glucose production and improves insulin sensitivity
  • Associated with modest weight loss and appetite reduction (unlike insulin/sulfonylureas, which cause weight gain)
  • In overweight type 2 diabetics, reduced diabetes-related endpoints, diabetes-related death, all-cause mortality, and myocardial infarction (UKPDS 34)
  • In women with PCOS, improves ovulation, clinical pregnancy, and menstrual frequency and may improve live-birth rate
  • No adequate human data support metformin for nutrient partitioning, fat loss, or performance enhancement in non-diabetic athletes/PED users; these uses are unproven
Safety

Adverse effects by system

Cardiovascular

No direct cardiotoxicity; in overweight type 2 diabetics metformin reduced myocardial infarction and cardiovascular/all-cause mortality (UKPDS 34). The serious cardiovascular danger is indirect: severe metformin-associated lactic acidosis can cause profound acidemia, hypotension, and hemodynamic collapse.

Hepatic

Not a recognized direct hepatotoxin (metformin is even studied in fatty liver). However, it is contraindicated in significant hepatic impairment because reduced lactate clearance raises lactic-acidosis risk. No adequate primary evidence of intrinsic metformin liver injury was identified.

Endocrine / HPTA

No suppression of the male hypothalamic-pituitary-gonadal (testosterone) axis; metformin is non-hormonal. In women with PCOS it lowers hyperinsulinemia and androgens and restores ovulation. It is not anabolic or androgenic.

Reproductive

In PCOS, improves ovulation and pregnancy rates. Metformin crosses the placenta; when used in pregnancy it is associated with lower mean birth weight than insulin, so obstetric use is an individualized specialist decision. No evidence of impaired fertility in men.

Neuropsychiatric

No well-established direct psychiatric adverse effects; no adequate human data demonstrate causal neuropsychiatric harm. (Untreated long-term B12 deficiency can indirectly contribute to cognitive/mood symptoms.)

Renal

Not directly nephrotoxic, but renally cleared: declining kidney function causes accumulation and is the principal precipitant of metformin-associated lactic acidosis. Dosing must be governed by eGFR, and iodinated-contrast procedures or acute kidney injury require temporary discontinuation.

Hematologic

Long-term use causes dose- and duration-dependent vitamin B12 depletion (mean ~19% fall vs placebo over 4.3 years; higher risk of B12 deficiency, NNH ~14), which can progress to megaloblastic anemia and peripheral neuropathy if unmonitored; homocysteine rises accordingly.

Dermatologic

No significant established dermatologic toxicity; only rare, isolated cutaneous reactions are reported, and no adequate primary evidence base was identified.

Recovery

HPTA suppression & recovery

Suppression: None / not applicable: metformin is non-hormonal and does not suppress the hypothalamic-pituitary-gonadal axis

Because metformin is not a hormonal or anabolic agent, it does not induce testosterone-axis suppression and no SERM-based recovery protocol applies to it. Metformin is a single agent used on its own metabolic merits, not part of any hormonal recovery scheme. Any concern about actual HPTA/testosterone suppression (e.g., from concurrent anabolic-androgenic steroid use) should be evaluated and managed by an endocrinologist, who may consider a single-agent SERM only if clinically indicated; do not self-direct hormonal recovery.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Renal function (serum creatinine and eGFR) at baseline and periodically, the key safety labSerum vitamin B12 (and consider methylmalonic acid) for long-term users, at least annually or if anemia/neuropathy appearsHbA1c and/or fasting glucose if used for glycemic purposesVenous lactate and blood gas if lactic acidosis is clinically suspectedCBC (to detect megaloblastic anemia from B12 depletion)

Cadence: Baseline labs before starting; renal function at least yearly (more often if eGFR 30-60, older age, or intercurrent illness); B12 at least annually with long-term use; hold the drug during acute illness, dehydration, or before contrast imaging ('sick-day rules').

Warning signs — seek care
  • Symptoms of lactic acidosis: unexplained deep/rapid breathing, severe muscle pain or weakness, unusual fatigue/malaise, abdominal pain, nausea/vomiting, feeling cold or hypothermia, drowsiness. Seek emergency care immediately
  • New numbness/tingling, sore tongue, or worsening fatigue/anemia (possible B12 deficiency)
  • Any acute illness with vomiting, diarrhea, or dehydration (stop and consult a clinician)
Do not use if

Contraindications

  • eGFR below 30 mL/min/1.73m2 (discontinue); reassess/reduce dose in the 30-60 range
  • Acute kidney injury or any acute condition risking renal hypoperfusion (severe dehydration, vomiting, diarrhea, shock)
  • Significant hepatic impairment (reduced lactate clearance)
  • Conditions predisposing to tissue hypoxia / hyperlactatemia: sepsis, acute or unstable heart failure, respiratory failure, recent MI
  • Heavy or binge alcohol use (impairs lactate metabolism)
  • Around administration of iodinated contrast media (temporary hold per imaging protocols)
  • History of metformin-associated lactic acidosis or metabolic acidosis
Combinations

Interaction profile

  • ModerateWith a GLP-1 / incretin agonist: Metabolic / glucose
  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • Metformin is not anabolic and has no proven body-composition or performance benefit in healthy people. Using it for that purpose is unsupported by human evidence and still carries real risk.
  • The single most important safeguard is protecting kidney function: know your eGFR, get it checked before starting and periodically, and never use metformin if kidney function is impaired.
  • Follow 'sick-day rules': stop metformin during vomiting, diarrhea, dehydration, serious infection, or before surgery/iodinated-contrast imaging, and restart only when well and renal function is confirmed.
  • Avoid heavy or binge alcohol use, which compounds lactic-acidosis risk.
  • Learn the warning signs of lactic acidosis (deep rapid breathing, severe muscle pain, extreme fatigue, abdominal pain, feeling cold/drowsy) and seek emergency care immediately. MALA is a medical emergency.
  • For long-term use, have vitamin B12 checked (and CBC); supplementation or dose review is appropriate if it falls.
  • Start low and titrate slowly, or use extended-release, to reduce GI side effects, but do not chase higher doses for effect.
  • Do not combine or self-manage metformin as part of any hormonal/PED regimen without physician oversight; any concern about testosterone-axis suppression belongs with an endocrinologist.
  • This is not a substitute for medical care. Metformin is a prescription drug, and its use should be supervised by a clinician with baseline and follow-up bloodwork.
Evidence

Citations (12)

Every clinical claim above is tied to a primary source. Overall evidence grade A — graded to the best available evidence for its core claims.

  1. 01

    Metformin lowers glucose chiefly by inhibiting hepatic gluconeogenesis via complex I inhibition/AMPK activation, with a redox-dependent mechanism at clinically relevant concentrations; AMPK is dispensable for acute glucose lowering.

    ReviewPMID 32897388 ↗

  2. 02

    Metformin inhibits hepatic gluconeogenesis and opposes glucagon action via defective cAMP/PKA signaling from complex I inhibition; AMPK activation confers insulin sensitivity but is dispensable for the glucose-lowering effect.

    ReviewDOI 10.1038/nrendo.2013.256 ↗

  3. 03

    Metformin's main effect is acute reduction of hepatic glucose production through mild transient inhibition of respiratory-chain complex I and downstream AMPK activation; it also improves PCOS ovarian function and reduces fatty liver.

    ReviewDOI 10.1042/CS20110386 ↗

  4. 04

    Oral bioavailability ~55%, elimination half-life ~5 h with good renal function, excreted unchanged in urine via organic cation transporters; clearance falls with renal function and plasma levels should stay below ~2.5 mg/L to limit lactic-acidosis risk.

    ReviewDOI 10.2165/11534750-000000000-00000 ↗

  5. 05

    Pooled data (347 studies, 70,490 patient-years) found no cases of and no increased risk of lactic acidosis with metformin versus other therapies; upper 95% limit ~4.3 cases/100,000 patient-years.

    Meta-analysisDOI 10.1002/14651858.CD002967.pub4 ↗

  6. 06

    Metformin-associated lactic acidosis occurs after acute overdose or with renal compromise and carries high mortality (~36% pooled); it usually coexists with precipitating illness such as sepsis or renal failure.

    Meta-analysisDOI 10.1007/s13181-019-00755-6 ↗

  7. 07

    In overweight newly-diagnosed type 2 diabetics, metformin reduced any diabetes-related endpoint by 32%, diabetes-related death 42%, all-cause mortality 36%, and myocardial infarction, with less weight gain and fewer hypoglycemic episodes than insulin/sulfonylureas; early metformin added to sulfonylurea showed a diabetes-related death signal.

    RCTPMID 9742977 ↗

  8. 08

    Long-term metformin lowered vitamin B12 ~19% versus placebo over 4.3 years, raised the absolute risk of B12 deficiency (NNH ~13.8) and low B12, and increased homocysteine; routine B12 monitoring is advised.

    RCTDOI 10.1136/bmj.c2181 ↗

  9. 09

    In women with PCOS, metformin improves ovulation, clinical pregnancy and menstrual frequency and may improve live-birth rate versus placebo, but causes more gastrointestinal side effects.

    Meta-analysisDOI 10.1002/14651858.CD003053.pub6 ↗

  10. 10

    Practical safety: reduce/reconsider dose at eGFR 30-60 and discontinue below 30 mL/min/1.73m2; contraindicated with liver/respiratory insufficiency, sepsis, acute heart failure; GI effects mitigated by titration or extended-release; screen B12 in long-term users; metformin crosses the placenta and is associated with lower birth weight than insulin.

    ReviewDOI 10.1111/dom.15749 ↗

  11. 11

    Renal function is best assessed by eGFR (CKD-EPI/MDRD) rather than creatinine alone for metformin eligibility; use is considered acceptable down to eGFR ~30 mL/min/1.73m2.

    CohortDOI 10.23736/S0391-1977.17.02626-8 ↗

  12. 12

    Extended-release metformin improves gastrointestinal tolerability and adherence; UKPDS-supported cardiovascular and mortality benefits appear partly independent of glycemic control.

    ReviewDOI 10.1007/s11892-017-0829-8 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice